NASDAQ$ORGO
Organogenesis Holdings Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Net revenue increased slightly, but net income and adjusted EBITDA decreased significantly due to a challenging environment in the physician office setting.
Organogenesis Holdings Inc. reported a 3% increase in net revenue for Q3 2022, reaching $116.9 million compared to $113.8 million in Q3 2021. However, net income decreased to $0.2 million from $12.6 million, and adjusted EBITDA decreased to $11.6 million from $21.7 million in the same period.
- Net revenue increased by 3% to $116.9 million compared to Q3 2021.
- Advanced Wound Care product revenue increased by 2% to $109.5 million.
- Surgical & Sports Medicine product revenue increased by 15% to $7.3 million.
- Net income decreased to $0.2 million compared to $12.6 million in Q3 2021.
Headline financials
Revenue & EPS history
Organogenesis · Revenue · Quarterly
$117M
Revenue by segment
Organogenesis · $117M total across 2 segments · Q3 2022
- Advanced Wound Care$110M+2.1%93.8%
- Surgical & Sports Medicine$7.3M+14.1%6.3%
Forward guidance
For the year ending December 31, 2022, the Company expects net revenue between $448 million and $465 million.
Tailwinds
- Net revenue from Advanced Wound Care products of between $420 million and $432 million.
- Net revenue from the sale of PuraPly products of between $252 million and $260 million.
- Net income in a range of approximately $12 million to $20 million
- Adjusted net income in a range of approximately $22 million to $31 million.
- EBITDA in a range of approximately $31 million to $42 million
Headwinds
- Net revenue of between $448 million and $465 million, representing a decrease of approximately 1% to 4% year-over-year
- Net revenue from Surgical & Sports Medicine products of between $28 million and $33 million, representing a decrease of approximately 11% to 25% year-over-year
- Adjusted EBITDA in a range of approximately $46 million to $58 million.
- Challenging environment in the physician office setting
- Continued competitive pressure from smaller amniotic players
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.8%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+0.5%
Avg return
30 days after
47%
17 / 36 earnings
Positive
+102.3%
Q4 2024
Best reaction
-42.4%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | -6.2% | -5.9% | |
| Q4 2025 | -13.8% | -22.4% | -38.1% | |
| Q3 2025 | +44.1% | +66.6% | +21.9% | |
| Q1 2025 | -42.4% | -43.6% | -43.3% | |
| Q4 2024 | +102.3% | +95.8% | +46.6% | |
| Q3 2024 | +26.6% | +10.3% | +0.9% | |
| Q2 2024 | +2.0% | +6.4% | -1.2% | |
| Q1 2024 | +31.2% | +23.2% | +19.0% | |
| Q4 2023 | -16.3% | -20.3% | -18.6% | |
| Q3 2023 | +6.8% | +22.9% | +62.4% | |
| Q2 2023 | -25.7% | -27.0% | -31.6% | |
| Q1 2023 | +29.7% | +43.2% | +81.1% | |
| Q4 2022 | +11.0% | -2.9% | -13.1% | |
| Q3 2022 | -18.3% | -11.5% | -17.7% | |
| Q2 2022 | -25.2% | -26.6% | -44.0% | |
| Q1 2022 | +4.6% | +9.8% | -9.3% | |
| Q4 2021 | +18.1% | +15.6% | +2.4% | |
| Q3 2021 | -6.4% | -5.0% | -16.1% | |
| Q2 2021 | +1.9% | +2.5% | +8.2% | |
| Q1 2021 | -15.3% | -11.3% | -28.7% | |
| Q4 2020 | +3.8% | +8.5% | +31.4% | |
| Q3 2020 | +8.2% | +5.2% | +20.2% | |
| Q2 2020 | +0.7% | +1.5% | +3.2% | |
| Q1 2020 | -9.9% | -18.8% | +4.2% | |
| Q4 2019 | -16.2% | +11.6% | +23.5% | |
| Q3 2019 | +10.3% | +8.8% | -36.1% | |
| Q2 2019 | -4.7% | -10.8% | +26.5% | |
| Q1 2019 | -0.4% | +1.0% | +0.7% | |
| Q4 2018 | -3.0% | -5.3% | -16.8% | |
| Q4 2017 | -3.0% | -5.3% | -16.8% | |
| Q2 2018 | +0.3% | +0.2% | +0.1% | |
| Q1 2018 | +0.0% | +0.4% | +0.3% | |
| Q3 2017 | +0.1% | +0.1% | -1.0% | |
| Q2 2017 | +0.0% | +0.1% | +1.5% | |
| Q1 2017 | -0.3% | -0.3% | +0.5% | |
| Q4 2016 | +0.0% | +0.0% | +0.0% | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro